The mapping of protein-protein interactions is key to understanding biological processes. Many technologies have been reported to map interactions and these have been systematically applied in yeast. To date, the number of reported yeast protein interactions that have been truly validated by at least one other approach is low. The mapping of human protein interaction networks is even more complicated. Thus, it is unreasonable to try to map the human interactome; instead, interaction mapping in human cell lines should be focused along the lines of diseases or changes that can be associated with specific cells. In this paper, an approach for combining different 'omics' technologies to achieve efficient mapping and validation of protein interactions in human cell lines is presented.
INTRODUCTION
Life involves a multiplicity of very complex processes of which a limited understanding has been achieved. In humans, these processes involve 30,000-60,000 genes, possibly the precursors of up to millions of different proteins in different functional states. These proteins are involved in the processes of cellular duplication, cellular maintenance, cellular responses to change and cell death. Techniques have been developed to study the functions of the different proteins in cells. Typically, these techniques have studied a single gene at a time. The development of genomics has changed researchers' perspective of discovery -it is now feasible simultaneously to ask thousands of questions about cells.
Our understanding of proteins as functional units has increased tremendously over the last 15 years. 1, 2 The notion that proteins consist of domains that infer some functionality as well as motifs that are implicated in different controls of the protein, such as regulation, is now appreciated. These domains and motifs to a great extent define the role of a protein and, thus, its interactions.
Although protein interactions are often portrayed as a static pathway cartoon, the reality is that protein interactions are very dynamic. Each protein is involved in multiple interactions during its life cycle. In some instances, interaction with other proteins occurs as the protein is being constructed by the ribosome. Localisation to a specific compartment or to structural proteins can be key in defining protein interactions. Furthermore, proteins will have different interactions depending on their activation states. This is clearly illustrated by signalling proteins, which are involved in multiple pathways depending on their state of phosphorylation. Therefore, protein interactions are dynamic processes defined by many variables that are not under the organism's control. The notion of mapping the human interactome is based more on science fiction than on reality. Simple mathematics would indicate that 60,000 genes represent 1.8 billion possible interactions to test, if each gene only led to one protein. Considering that genes lead to multiple proteins in different states, this could represent more than 500 billion possible interactions to test. This is way beyond the ability of current technologies.
More importantly, mapping of protein-protein interactions can be very useful when applied in a disease-or target family-focused approach using relevant model systems. Technologies have been developed over the years to map proteinprotein interactions. In this paper, these technologies are reviewed and their limitations discussed; their synergetic applications with other technologies to elucidate protein interactions in wellfocused applications will also be examined.
MAPPING PROTEINÀPROTEIN INTERACTIONS
High throughput approaches, such as the two-hybrid method, 3 have been developed for the mapping of proteinprotein interactions. These data have been made available through publications and protein-protein interaction databases.
The Grid 4 and Bind 5 are examples of such databases. Unfortunately, the data in these databases, at best, represent a noisy low resolution approximation of proteinprotein interactions, and suffer from a lack of validation. In reality, all of these high throughput technologies take static pictures of the protein-protein interaction properties, average the results over different cell states and often study the gene of interest in an extraneous environment. Although the results of these technologies may be precise, there is no guarantee of accurate representation of the real world.
So far, the public high throughput mapping of protein-protein interactions has been uncoordinated, and the likelihood of achieving cross-validation of the results is low. Most of the high throughput mapping of protein-protein interactions have been reported in yeast -as illustrated in Figure 1 , which shows the state of published protein-protein interactions in yeast. The right-hand pie chart shows the proportion of interactions that were validated in another The level of complexity greatly increases when dealing with human cells, and therefore the mapping of proteinprotein interactions must be approached differently. The mapping of the interactome using one or a few cell lines will only establish the basal level of protein-protein interactions. In many instances, the results will be irrelevant to the protein in its true state and in the true processes in which it is involved.
The remaining challenge is to design high throughput approaches that combine different technologies for the rapid discovery and validation of proteinprotein interactions. It is proposed that this can be solved by focusing on the relevant subset of the interactome, as described below.
CELL STATE/DISEASE INTERACTOME
The most relevant approach for the mapping of valid protein-protein interactions is to study a subset of the interactome in a targeted approach. For example, instead of trying to map all of the interactions in a cell, one could more specifically focus on the interactions of proteins that show 'changes' during disease progression or through stimulation/treatment of specific cells. Techniques are already in place to measure 'changes'. Gene chip 6, 7 and serial analysis of gene expression (SAGE) 8 can be used to measure changes in gene expression. Differential proteomics and differential phosphoproteomics 9,10 can also be used to measure changes in protein expression and changes in protein phosphorylations. These techniques can provide a list of genes that might be relevant to targeting the mapping of protein-protein interactions.
The technology for discovering protein-protein interactions requires the experiments to be performed in cell models. The changes that were observed in the tissues can easily be verified to occur also at the cell model level. The focusing on the subset of the interactome that is changing due to stimulation or disease progression inherently infers that the upstream pathways and regulations are in place. Thus, this approach increases the likelihood of discovering meaningful interactions.
The discovery and validation of protein-protein interactions requires access to the protein of interest or to its gene. Complementary DNA (cDNA) clones for the genes of interest can be obtained from commercial sources, such as the Invitrogen and the Kazusa collections, as well as from academic endeavours such as the FlexGene repository.
11 If they are not available, they can be cloned de novo using standard molecular procedures. The clones can be moved into transfection systems and used to perform different experiments rapidly. For example, the Gateway system 12 can be used rapidly to introduce many genes into an entry vector (Figure 2 ). They can then easily be transferred from their entry vectors to different destination vectors designed for specific experiments. For example, the destination vectors can be designed to perform epitope tagging immunopurification, to produce green fluorescent protein (GFP) fusion proteins for the study of protein localisation, to perform the two-hybrid approach and to express large amounts of proteins for larger scale purification. This greatly reduces the amount of molecular biology needed to perform these different experiments.
FIRST PASS MAPPING
The first pass mapping of protein-protein interactions should be performed in relevant cell lines and using a technology that minimises the change introduced by the measurement itself. In humans, the number of possible interactions based on 30,000-60,000 genes is staggering. Techniques that ask the specific question: 'Is protein A interacting with protein B?' are not appropriate for the first pass of high throughput mapping, as they require researchers to possess all the genes. Instead, the best approach is to rely on techniques that ask the question: 'What are the proteins that interact in a specific cell line or tissue with protein A?' Interestingly, this does not require any prior knowledge of the interacting proteins. Mass spectrometry (MS)-based approaches can rapidly identify proteinprotein interactions. MS-based techniques have been coupled with high throughput immunopurification to study proteinprotein interactions. 13 The sensitivity of MS has continuously improved, thus significantly reducing the requirement for cellular material. It is now feasible to study protein-protein interactions by MS using a single plate of human cell lines.
These approaches generally consist of the selective purification and enrichment of a bait protein and its associated proteins from cell or tissue lysate. The protein complexes are allowed to form either in the cells (in vivo) or in solution (in vitro). In the in vivo approach, a clone coding for a tagged bait protein is transfected into cells, and the expressed protein and its interacting protein partners are extracted a few days later using the tag present on the bait. For example, immunopurification using antibodies against the FLAG tag, 14 or based on the tandem affinity purification (TAP) tag approach, 15 are often applied to the purification/ enrichment of protein complexes that are formed in the cells. One advantage of combining bait tagging with immunopurification/affinity purification with MS is that the interactions formed inside a relevant cell or tissue can be analysed. Alternatively, for small genomes, it is possible to use homologous recombination approaches to insert a tag directly in the genome. Purified proteins from either the in vivo or in vitro approaches are then separated by one-dimensional gel electrophoresis. The protein bands are excised and digested into peptides using trypsin. Each tryptic peptide mixture is analysed through high performance nanoflow liquid chromatography coupled to an electrospray ionisation tandem mass spectrometer. The mass spectrometer generates information that can be used to identify the proteins present in each gel band. This approach identifies the interactors associated with the bait protein.
The author and colleagues recently published a paper on the study of protein-protein interactions by MS 16 and demonstrated its application in human cell lines using a flag-tagged pICLn. Known and novel interactors of pICLn were identified. Two groups have also demonstrated the high throughput identification of protein-protein interactions in yeast: Gavin et al. 17 used the TAP tag approach to study 589 yeast genes and Ho et al. 18 used the flag tag approach to study 725 yeast genes.
The TAP tag approach tends to be cleaner by focusing on strong interactions. 19 By contrast, the FLAG tag approach allows a wider range of interactors to be observed at the cost of potentially higher noises. Fortunately, the precision of the MS-based interaction mapping can be significantly enhanced by simply repeating the experiments. In addition, non-specific interactions can be rapidly filtered using prior knowledge gained from mapping the interactions from other genes. In fact, an empirical frequency of interaction can be calculated for all of the proteins ever observed. The promiscuous interactors will have a higher frequency across functionally different baits. Alternatively, statistical methods have been described to assess the confidence level in the accuracy of protein-protein interaction datasets. 20, 21 So far, no large-scale studies have been published on using these methodologies in a more focused disease or functionally driven approach. Nevertheless, it has been the author's experience with human protein interactions mapping that the cell system must be judiciously chosen for the disease of interest or the target of interest. The results of MS-based interactions mapping provide a first pass resolution of the possible interactors related to a gene of interest. The first pass approach provides a list of potential interactors. A second stage, high throughput approach is necessary to validate the interactors. Different strategies can be designed to enhance the resolution of the proteinprotein interaction map.
Focusing on what seems to change
By the end of the first pass exercise, a list of potentially interacting proteins is generated in different states of disease or different stimulation. In the author's experience, on average 5À10 proteins are reproducibly associated with particular bait. Potentially, this could represent a large set of interactions to validate. It is possible to reduce this list by focusing on key interactions, ie the ones associated with a 'change'. This change can be a gene expression change, protein expression change or post-translational modification (PTM) of proteins such as phosphorylation. Using this approach, a smaller list of interactions can be first selected for the next stage validation. This does not mean that the rest of the interactions are not true, but they might not be key to the disease or stimulation under study.
VALIDATION IN A MODEL SYSTEM
The next step is to validate the proteinprotein interactions and to deconstruct immunopurification results into pathways and complexes. Different techniques are available as secondary approaches to enhance the confidence level in proteinprotein interactions.
Two-hybrid and other systems
The first technique, called the two-hybrid method, was introduced for studying binary protein-protein interactions. 22 It is a rapid screen to determine if protein A is binding to protein B. Briefly, in the twohybrid technique, the proteins that were discovered in the first pass mapping can be expressed in yeast to create two arrays of yeast cells. The first array (the bait array) expresses the different proteins each fused with the DNA-binding domain of a transcription factor that lacks the transcription activation domain. The second array (the prey array) expresses the same proteins fused to the transcription activation domain. The two-yeast arrays are then mated in order to transfer the coding material and to allow both fusion proteins to be expressed in the same cells. The fusion protein made of the DNAbinding domain and the protein of interest binds to the promoter region of the reporter gene. If the prey protein interacts with the bait protein, the activation machinery recognises the preybound activation domain and the reporter gene is transcribed. The two-hybrid approach has previously been used to map protein-protein interactions in Saccharomyces cerevisiae, 23, 24 Helicobacter pylori, 25 Escherichia coli, 26 hepatitis C, 27 vaccinia virus 28 and Caenorhabditis elegans.
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Different mammalian two-hybrid systems were developed for the detection of protein-protein interactions in a mammalian cell line. For example, Suzuki et al. 30 reported the mapping of proteinprotein interactions using mouse fulllength cDNAs and the mammalian two-hybrid approach to screen 3,500 bait with 3,400 prey proteins for possible interactions. The throughput of the mammalian two-hybrid remains low compared with the yeast two-hybrid system.
The two-hybrid approach is known to have serious limitations. In particular, it is poorly applicable to membrane proteins. Some proteins do not fold properly as hybrid proteins. Protein interactions which are dependent on certain secondary modifications may not be detected by the yeast two-hybrid approach. More importantly, those proteins that are taken out of context and where, therefore, the interactions do not occur in their normal cellular environment, can often provide positive yeast two-hybrid results. Using the two-hybrid approach to validate the results from the first pass mapping must be considered carefully. The rule of thumb should be that the two-hybrid system should only be considered if it does validate the results from the first pass; however, negative results from the twohybrid system should not invalidate the results obtained in the first pass.
Other methods have been developed for reporting protein-protein interactions by the direct or indirect activation of enzymes. Wehrman et al. 31 described a method to monitor protein-protein interactions in mammalian cells using the â-lactamase enzyme. In this approach, the researchers used the AE and ø fragments of â-lactamase to build a protein-interaction reporting assay. Fusion proteins can be constructed with the AE and ø fragments, and the interaction can be tested by cotransfection in mammalian cells. If the two fusion proteins interact together, the AE and ø fragments are brought into close proximity and the activity of â-lactamase is turned on, allowing growth in ampicillin-containing media. Another approach, called mammalian proteinprotein interactions trap (MAPPIT), was recently described by Eyckerman et al. 32 Briefly, this method relies on the mutation of critical tyrosine residues on the cytosolic domains of a receptor that results in the loss of STAT activation while JAK proteins are still activated. The recruitment to the membrane of any other proteins containing a STATbinding site can reactivate the signalling. Fusion proteins can then be created to take advantage of this screen for proteinprotein interactions. The activation of the signalling pathway indicates the occurrence of an interaction between two fusion proteins.
The application of these binary interaction validation methodologies can be focused on the bait/prey sets that were previously generated. This means that for every bait there will be (on average) at most 15À45 interactions to verify if they are all linked to 'changes'. Thus, the twohybrid, â-lactamase and MAPPIT approaches could be simultaneously used to validate the interactions. At this stage, there is not yet a clear understanding of the overlap between these approaches; the â-lactamase and the MAPPIT approaches have not yet been widely applied. The information obtained by these approaches can be overlaid with the first pass dataset to reinforce some of the interactions.
Reciprocal MS-based protein interaction mapping
Alternatively, the methods that were used in the first pass mapping of proteinprotein interactions can be used to decipher the protein-protein interactions from the immunopurification results by turning the prey proteins into baits. It is not guaranteed that the prey-turned-intobait proteins will necessarily associate with the first pass bait protein. This means that either the proteins are only interacting through secondary proteins or that the stoichiometry is not favourable. Thus, this approach deciphers interactors, but does not necessarily validate them.
Co-localisation
Co-localisation can be used to validate protein-protein interactions. A high throughput approach to determine the localisation of GFP-labelled proteins has been described and applied in yeast. 33 In this approach, yeast strains were created for 4,156 proteins that were successfully expressed. Microscopic imaging was used to determine the localisation of the GFPlabelled proteins, 1,839 of these proteins indicated localisations other than in the nucleus or the cytoplasm. The large-scale mapping of protein localisations in human cells using this approach has not been reported. The overlapping of colocalisation data with protein interactions and gene expression and other genomics datasets can help reinforce the validity of protein-protein interactions.
Computationally based approach to combining different datasets
Computationally based approaches have been reported to combine and predict the validity of protein-protein interactions using different sets of 'omics' information. 34, 35 To date, most of these efforts have focused on yeast, which has been the most comprehensively studied cellular system by different omics technologies. More recently, Jansen et al. 36 described a Bayesian network approach to predict protein-protein interactions using genomic data, such as the results obtained from pull-down experiments, two-hybrid methods and expression datasets. They achieved better sensitivity by combining these different datasets through Bayesian networks. These types of computational approaches are important in efficiently combining different datasets.
CONCLUSION
The mapping of protein-protein interactions in human cells requires an experimental design directed to answer specific questions about the interactions of disease-associated genes. Different 'omics' approaches can be incorporated into the experimental design to reinforce the validity of the interactions. In this paper, one model of experimental design for studying protein-protein interactions has been presented; however, it is important to realise that the understanding of the 'space' that some of these 'omics' technologies can sample is still poor.
